헬스케어 IPO 시장 예측(-2032년) : 사업체 유형별, IPO 규모 및 구조별, 투자자 유형별, 상장 시장별, 치료 영역별, 지역별 세계 분석

According to Stratistics MRC, the Global Healthcare IPOs Market is accounted for $1.8 billion in 2025 and is expected to reach $2.8 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Healthcare IPOs refer to the initial public offerings of companies operating within the healthcare sector, including pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health. These IPOs allow private healthcare firms to raise capital by offering shares to the public for the first time, enabling expansion, research, and innovation. Healthcare IPOs are often driven by breakthroughs in medical technology, regulatory approvals, and investor interest in life sciences. They play a crucial role in funding high-growth ventures and advancing public access to cutting-edge treatments. Market performance can be influenced by clinical trial results, policy changes, and broader economic conditions.

Market Dynamics:

Driver:

Rapid innovation in health tech

Rapid innovation in health technology is a key driver of the Healthcare IPOs Market. Breakthroughs in biotechnology, digital health, AI-driven diagnostics, and wearable medical devices are transforming patient care and creating high-growth opportunities. These advancements attract investor interest and accelerate the path to public offerings. Startups and established firms alike seek IPOs to fund R&D, scale operations, and commercialize novel treatments. As health tech continues to evolve, it fuels a dynamic IPO landscape that supports innovation and expands access to cutting-edge healthcare solutions.

Restraint:

Stricter IPO criteria

Stricter IPO criteria present a significant restraint to the Healthcare IPOs Market. Regulatory bodies and stock exchanges have tightened listing requirements to ensure transparency, financial stability, and investor protection. These include rigorous financial disclosures, clinical trial validations, and governance standards. While these measures enhance market integrity, they can delay or deter IPO plans, especially for early-stage healthcare firms. Navigating these hurdles requires robust compliance strategies and investor readiness, making it challenging for some companies to access public capital markets efficiently.

Opportunity:

Digital healthcare expansion

The expansion of digital healthcare presents a major opportunity for the Healthcare IPOs Market. Telemedicine, remote monitoring, AI-powered diagnostics, and health data platforms are reshaping care delivery. As demand for accessible, tech-enabled healthcare grows, digital health startups are attracting significant venture capital and preparing for public listings. IPOs provide the funding needed to scale platforms, enhance cybersecurity, and expand global reach. This digital transformation is unlocking new revenue streams and positioning healthcare IPOs as a gateway to next-generation medical innovation.

Threat:

Regulatory complexity

Regulatory complexity poses a notable threat to the Healthcare IPOs Market. Navigating diverse and evolving healthcare regulations across jurisdictions can be daunting for companies seeking to go public. Compliance with clinical trial protocols, data privacy laws, and financial reporting standards adds layers of risk and cost. Delays in regulatory approvals or policy shifts can impact valuation and investor confidence. To mitigate these challenges, firms must invest in legal expertise, transparent governance, and adaptive strategies to align with global regulatory expectations.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the Healthcare IPOs Market. While it disrupted clinical trials and delayed regulatory reviews, it also spotlighted the importance of healthcare innovation. Companies developing vaccines, diagnostics, and digital health solutions experienced heightened investor interest and accelerated IPO timelines. The crisis underscored the value of agile, science-driven firms, leading to a surge in healthcare listings. Post-pandemic, the market continues to benefit from increased public and private investment in health resilience and technological advancement.

The biotechnology firms segment is expected to be the largest during the forecast period

The biotechnology firms segment is expected to account for the largest market share during the forecast period, as biotech companies are at the forefront of medical innovation, developing therapies for cancer, rare diseases, and chronic conditions. Their high growth potential and frequent breakthroughs attract strong investor interest. IPOs provide critical funding for clinical trials, regulatory approvals, and commercialization. As personalized medicine and gene therapies gain traction, biotech firms dominate the IPO landscape, driving both capital inflow and transformative healthcare advancements.

The cardiology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cardiology segment is predicted to witness the highest growth rate, due to rising prevalence of cardiovascular diseases, aging populations, and demand for advanced diagnostics and treatments fuel growth. Companies developing innovative cardiac devices, digital monitoring tools, and minimally invasive procedures are gaining investor attention. IPOs enable these firms to expand R&D, scale production, and enter new markets. As heart health remains a global priority, the cardiology segment's rapid innovation and clinical relevance position it for accelerated IPO activity and sustained growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to region's expanding healthcare infrastructure, rising middle-class population, and government support for biotech innovation drive market growth. Countries like China, India, and South Korea are fostering vibrant startup ecosystems and easing access to capital markets. Local exchanges are attracting healthcare listings, while global investors seek exposure to Asia's dynamic health sector. This momentum positions Asia Pacific as a dominant force in healthcare IPO activity.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to region's robust life sciences ecosystem, strong venture capital presence, and favorable regulatory environment support rapid IPO growth. U.S.-based biotech and medtech firms lead in innovation, frequently leveraging IPOs to fund clinical trials and commercialization. The rise of digital health and personalized medicine further fuels listings. With mature capital markets and investor appetite for healthcare innovation, North America remains a hotspot for high-growth healthcare IPOs.

Key players in the market

Some of the key players in Healthcare IPOs Market include Galderma S.A., BrightSpring Health Services, Concentra Group Holdings, PACS Group Inc., CG Oncology Inc., Tempus AI Inc., Auna S.A., Emcure Pharmaceuticals Ltd., Sai Life Sciences Ltd., Sagility India Ltd., Hinge Health, Omada Health, Kyverna Therapeutics Inc., Bicara Therapeutics Inc., Ardent Health Partners Inc.

Key Developments:

In January 2025, Syensqo and Ardent Process Technologies have formalised a strategic partnership to accelerate point-source carbon capture and olefin-paraffin separation technologies, combining Syensqo's materials science prowess and industrial scale with Ardent's high-performance membrane solutions.

In October 2024, L'Oreal Groupe has acquired a 10 % stake in Galderma Group AG and entered a strategic scientific partnership, combining Galderma's dermatology-solutions expertise with L'Oreal's strengths in skin-biology, diagnostic tools and evaluation methods to accelerate innovation in the aesthetics and dermatology space.

Entity Types Covered:

• Pharmaceutical Companies
• Biotechnology Firms
• Medical Device Manufacturers
• Diagnostics & Laboratory Services
• Healthcare Services & Providers
• Digital Health & Health IT

IPO Sizes & Structures Covered:

• Small-cap IPOs
• Mid-cap IPOs
• Large-cap IPOs
• SPAC Mergers & Reverse Mergers

Investor Types Covered:

• Institutional Investors
• Retail Investors
• Venture Capital & Private Equity
• Strategic Corporate Investors

Listing Venues Covered:

• Major Exchanges
• Regional Exchanges
• Cross-Listings & ADRs

Therapeutic Areas Covered:

• Oncology
• Cardiology
• Rare Diseases & Orphan Drugs
• Gene & Cell Therapies
• Digital Therapeutics & AI Diagnostics

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Healthcare IPOs Market, By Entity Type

• 5.1 Introduction
• 5.2 Pharmaceutical Companies
• 5.3 Biotechnology Firms
• 5.4 Medical Device Manufacturers
• 5.5 Diagnostics & Laboratory Services
• 5.6 Healthcare Services & Providers
• 5.7 Digital Health & Health IT

6 Global Healthcare IPOs Market, By IPO Size & Structure

• 6.1 Introduction
• 6.2 Small-cap IPOs
• 6.3 Mid-cap IPOs
• 6.4 Large-cap IPOs
• 6.5 SPAC Mergers & Reverse Mergers

7 Global Healthcare IPOs Market, By Investor Type

• 7.1 Introduction
• 7.2 Institutional Investors
• 7.3 Retail Investors
• 7.4 Venture Capital & Private Equity
• 7.5 Strategic Corporate Investors

8 Global Healthcare IPOs Market, By Listing Venue

• 8.1 Introduction
• 8.2 Major Exchanges
• 8.3 Regional Exchanges
• 8.4 Cross-Listings & ADRs

9 Global Healthcare IPOs Market, By Therapeutic Area

• 9.1 Introduction
• 9.2 Oncology
• 9.3 Cardiology
• 9.4 Rare Diseases & Orphan Drugs
• 9.5 Gene & Cell Therapies
• 9.6 Digital Therapeutics & AI Diagnostics

10 Global Healthcare IPOs Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Galderma S.A.
• 12.2 BrightSpring Health Services
• 12.3 Concentra Group Holdings
• 12.4 PACS Group Inc.
• 12.5 CG Oncology Inc.
• 12.6 Tempus AI Inc.
• 12.7 Auna S.A.
• 12.8 Emcure Pharmaceuticals Ltd.
• 12.9 Sai Life Sciences Ltd.
• 12.10 Sagility India Ltd.
• 12.11 Hinge Health
• 12.12 Omada Health
• 12.13 Kyverna Therapeutics Inc.
• 12.14 Bicara Therapeutics Inc.
• 12.15 Ardent Health Partners Inc.